BRASILIA - Brazilian pharmaceutical company União Química said on Friday that, together with the Russian Direct Investment Fund (RDIF), it has requested regulatory approval for emergency use of Russia's COVID-19 vaccine Sputnik V.
The request, filed with Brazilian health regulator Anvisa, seeks approval for the use of 10 million doses of Sputnik V in Brazil in the first quarter of 2021, the company said in a statement issued in Moscow. Anvisa officials said the Russian vaccine would have to be submitted to Phase III clinical trials in Brazil before its use can be authorized.